GT Medical Technologies

About GT Medical Technologies

GT Medical Technologies is redefining the treatment of operable brain tumors. Founded in 2017 and headquartered in Tempe, Arizona, the company was established by brain tumor specialists and medical device innovators seeking to address critical gaps in conventional brain tumor treatment. Operating at the intersection of medical technology and neuro-oncology, GT Medical develops therapies that integrate directly into the surgical workflow to deliver immediate, localized treatment at the point of care. Its flagship FDA-cleared technology, GammaTile®, (also known as tile-based radiation therapy, or TBRT) commercially launched in 2019 and has since been adopted at more than 150 cancer centers across the United States in collaboration with leading neurosurgeons and radiation oncologists nationwide.

Flagship Technology: GammaTile® Therapy

GammaTile is a tile-based radiation therapy designed for patients with operable brain tumors. The therapy consists of a bioabsorbable collagen tile embedded with cesium-131 radiation sources that is implanted directly into the tumor cavity at the time of surgical tumor removal.

By delivering immediate, localized radiation from within the surgical cavity, GammaTile TBRT is designed to target remaining tumor cells while limiting radiation exposure to surrounding healthy brain tissue.

Clinical Trials

GT Medical Technologies sponsors a growing portfolio of clinical research evaluating GammaTile TBRT across multiple brain tumor indications. These studies include prospective, multi-center clinical trials designed to assess the safety, effectiveness, and real-world outcomes of GammaTile in both newly diagnosed and recurrent brain tumors, as well as in combination with standard-of-care therapies.

Clinical Trial	Target Patient Population	Purpose
ROADS (NCT04365374)	Patients with newly diagnosed brain metastases who are eligible for surgical removal.	To determine if immediate GammaTile therapy implanted during surgery is as effective as conventional post-surgical Stereotactic Radiotherapy (SRT) at preventing tumor recurrence, while maintaining safety and quality of life.
Intracavity Carrier-embedded Cs-131 Brachy Study (NCT04690348)	Patients with recurrent brain metastases undergoing surgery.	To evaluate whether placing Cs-131 brachytherapy (GammaTile) into the cavity at the exact time of surgery prevents tumors from growing back compared to the standard approach of surgery alone.
GESTALT (NCT05342883)	Patients with newly diagnosed glioblastoma (GBM) eligible for surgery.	To assess the safety and feasibility of adding immediate GammaTile radiation at the time of surgery to the standard regimen of post-operative External Beam Radiation (EBRT) and chemotherapy, closing the gap of treatment delay during surgical healing.
BRIDGES (NCT07195591)	Patients with newly diagnosed glioblastoma (GBM) eligible for surgery.	To determine if delivering immediate, targeted radiation via GammaTile at the time of tumor excision improves overall survival and reduces recurrence compared to the standard of care radiation regiment, which typically delays radiation therapy by several weeks.
STaRT Patient Registry (NCT04427384)	Any patients with brain tumors who have been treated with GammaTile (STaRT).	An observational Phase 4 registry designed to collect and evaluate real-world clinical data and patient-reported outcomes regarding the long-term effectiveness and safety of GammaTile therapy in routine clinical practice.

Additional investigator-initiated trials are further expanding the evidence base supporting GammaTile in diverse brain tumor indications.

Leadership Team

GT Medical Technologies is led by a multidisciplinary team of clinicians, scientists, and medical device executives with deep expertise in neuro-oncology and radiation oncology. The team combines clinical and commercial experience to advance the company's mission of improving outcomes for patients with operable brain tumors. Key leaders include Chief Executive Officer Per Langoe; Chief Medical Officer Dr. Michael Garcia, a radiation oncologist who leads clinical and scientific strategy; and Co-Founder and Chief Technology Officer Dr. David G. Brachman, a radiation oncologist and innovator in surgically targeted radiation therapies. Together, they guide the development, clinical adoption, and expansion of GammaTile TBRT across leading cancer centers nationwide.

For product information or assistance, or to be connected with your GammaTile Representative, contact:

GammaTile Customer Service Department
(833) 662-0044 | customerservice@gammatile.com